FDA approves latest Humira near-copy, as dozens of biosimilars head for market

The FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of these cheaper near-copies teed up to compete when the originator’s patent expires in 2023.